Abstract 3337
Background
Family caregivers of cancer patients report high burden leading to poor emotional and physical health. Knowledge of predisposing factors could contribute to its prevention or early detection. The aim of this study was to identify the factors related to caregiver burden among caregivers of cancer patients.
Methods
90 cancer patients hospitalised in two oncological wards in Crete, Greece and their primary caregivers (PCs) were included in the study. They both provided their demographics, while PCs completed the Bakas Caregiving Outcomes Scale (BCOS), comprising 15 self-rated items (7-point response scale with reduced BCOS scores implying higher burden) and the Hospital Anxiety and Depression Scale (HADS), comprising 14 self-rated items in a 4-point scale (0-3).
Results
Most patients were male (52.2%) and most PCs were female (67.8%), aged 50 to 74 years old (52.2% and 54.4% respectively). The majority of PCs (44.3%) were spouses. The mean of burden using the BCOS was 56.7 (SD 10.9) (range 22-100), 75.6% experienced no burden (total score > 52.5), while 24.4% reported high burden (total score < 52.5). High level of anxiety (≥ 11) using the HADS was reported by 55.6% of PCs and high level of depression (≥ 11) by 20%. The correlations between BCOS and HAD-Anxiety (r=-0.401, p < 0.001) and BCOS and HAD-Depression (r=-0.402, p < 0.001) were negatively moderate. Older age PCs appear to experience higher burden (r=-0.278, p = 0.008) and depression (r = 0.372, p < 0.001), while the duration of caregiving also imposes more anxiety (r=-0.322, p = 0.002) and depression (r = 0.262, p = 0.013). On the other hand, depression correlates negatively with the educational background of both patients (r=-0.247, p = 0,019) and caregivers (r=-0.283, p = 0.007).
Conclusions
Primary caregiver anxiety, depression, age, the duration of caregiving and the patient and caregiver educational background are factors related to caregiver burden. Larger sample studies are needed to better identify the factors affecting caregiver burden.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2262 - Real world experience of Nivolumab therapy in Metastatic Renal Cancer patients: a 3 year multi-centre review
Presenter: Joanna Hack
Session: Poster Display session 3
Resources:
Abstract
4441 - “A pilot study of tremelimumab (treme) with or without cryoablation (cryo) in patients (pts) in metastatic renal cell carcinoma (mRCC).”
Presenter: Matthew Campbell
Session: Poster Display session 3
Resources:
Abstract
2613 - Lenvatinib (Len) alone or in combination with Everolimus (Eve) in heavily pretreated patients (pts) with metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitors (ICI) and VEGFR-targeted therapies: A single-institution experience
Presenter: Andrew Wiele
Session: Poster Display session 3
Resources:
Abstract
3249 - Weight loss is an underestimated adverse event with cabozantinib in patients with metastastic renal cell carcinoma (mRCC).
Presenter: Emeline Colomba
Session: Poster Display session 3
Resources:
Abstract
2405 - Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma.
Presenter: Felix Lefort
Session: Poster Display session 3
Resources:
Abstract
4020 - Skeletal muscle loss as an adverse event during Cabozantinib treatment in patients with metastatic renal cell carcinoma
Presenter: Carolina Alves Costa Silva
Session: Poster Display session 3
Resources:
Abstract
2407 - Long term relative survival (RS) in patients with primary metastatic kidney cancer (primary mRCC): an analysis of 2,167 patients from the Austrian National Cancer Registry (ANCR).
Presenter: Monika Hackl
Session: Poster Display session 3
Resources:
Abstract
2470 - Advanced renal cell carcinoma: first results from the prospective research platform CARAT for patients with mRCC in Germany
Presenter: Peter Goebell
Session: Poster Display session 3
Resources:
Abstract
1533 - Are immune checkpoint inhibitors a valid option for papillary Renal Cell Carcinoma? Transcriptomic characterization of the immune infiltrate
Presenter: Manon De Vries-brilland
Session: Poster Display session 3
Resources:
Abstract
3367 - Treatment-Free Survival, With and Without Toxicity, as a Novel Outcome Applied to Immuno-Oncology Agents in Advanced Renal Cell Carcinoma
Presenter: Meredith Regan
Session: Poster Display session 3
Resources:
Abstract